Cardinal Health and Jvion will continue their commitment to provide technology solutions to drive better care, smarter spending, and improved outcomes. Building on the collaboration that originated in 2018, Cardinal Health is now the exclusive reseller of Jvion oncology solutions for community-based oncology practices, including the powerful and proven Jvion CORE™ artificial intelligence (AI) platform.
According to the Institute of Medicine, by 2030 the number of cancer survivors in the U.S. is projected to increase by 31.4 percent to 22.2 million, and the yearly rate of new cancer diagnoses will be 2.3 million by 2023. With the population of cancer patients and survivors increasing, community oncology providers need solutions to identify those who are most at risk of adverse health events, especially as the focus on value-based care continues to evolve.
To address this need, Cardinal Health and Jvion collaborated to bring the artificial intelligence (AI) decision support tool, the CORETM, to help oncologists identify high-risk patients and to assist with managing their care. By using Jvion’s AI, practices can provide high-quality cancer care that is patient-centered, outcomes focused, and cost effective while reducing the cognitive burden that is often placed on physicians and clinical staff.
By using prescriptive analytics, the tool goes well beyond just risk predictions to guide the best actions or interventions that are related to socio-economic or clinical factors that can change the outcomes for the patient. The CORE identifies patients at risk of a poor outcome, the clinical and non-clinical factors driving that risk, and the intervening actions that will most likely improve quality and the patient experience.
Click here to view an infographic about the value of AI and community oncology.
To learn more about the Jvion CORETM clinical AI tool and to request a demo here.